Tianjin Medical University Cancer Institute And Hospital

This phase 2 trial tests whether a mix of immunotherapy (iparomlimab and tuvonralimab), chemotherapy (gemcitabine and oxaliplatin), and a targeted drug (lenvatinib) can shrink bile duct and gallbladder cancers enough to be surgically removed. About 29 adults with locally advanced…

This phase 2 trial tests a combination of two drugs—Sacituzumab tirumotecan and Tagitanlimab—in 47 people with PD-L1-positive advanced triple-negative breast cancer that has already been treated. The goal is to see if the combo can shrink tumors or slow the disease. The study is …

This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery in 26 patients with locally advanced esophageal cancer. The goal is to see if this approach can completely eliminate cancer cells in the removed tis…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and bevacizumab—in 31 adults with advanced non-squamous lung cancer that has worsened after initial treatment. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive t…

This early-phase trial tests whether adding an experimental immunotherapy drug called Retlirafusp alfa to standard chemotherapy can improve outcomes for people with gastroesophageal junction cancer. About 30 participants will receive the combination before surgery, then some may …

This study tests whether giving chemotherapy directly into the liver along with standard chemo pills and IV drugs can help prevent colorectal cancer from coming back after surgery to remove tumors from the liver. About 28 adults who have had successful surgery and show no remaini…

This study tests a three-drug combination (donafenib, chemotherapy via liver artery infusion, and sintilimab) as a first treatment for people with liver cancer that cannot be removed by surgery. About 90 adults aged 18-80 with advanced liver cancer will participate. The goal is t…

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…

This study tests different drug combinations for people with extensive-stage small cell lung cancer who have not had prior treatment. Participants are assigned to a treatment arm based on specific biomarkers in their tumor, such as DLL3 or Myc. The goal is to see if these persona…

This study is for people with esophageal cancer that did not shrink after initial treatment. It tests whether adding low-dose radiation to a combination of immunotherapy (toripalimab) and chemotherapy can improve outcomes. Participants will receive the treatment before surgery, a…

This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in t…

This phase 2 trial tests whether adding the drug retlirafusp alfa to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Eighteen participants will receive the drug combo, then undergo surgery, followed by a year of m…

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This phase 2 study is testing fluzoparib, a daily pill, as a maintenance therapy for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The trial will enroll 72 participants with or without BRCA gene mutations. The goal is to…

This phase 2 trial tests iruplinalkib tablets as a daily treatment after surgery for people with stage IA ALK-positive non-small cell lung cancer who have high-risk factors. The goal is to see if the drug can prevent the cancer from coming back. About 28 participants will take th…

This phase 2 trial tests whether adding an experimental immunotherapy (QL1706) to standard chemotherapy and targeted drugs can better eliminate HER2-positive breast cancer before surgery. About 188 people with early or locally advanced disease will be randomly assigned to receive…

This phase 2 trial tests whether combining two immune-boosting antibodies (iparomlimab and tuvonralimab) with precise, high-dose radiation (SBRT) can better control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the drug combination …

This Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just…

This phase II trial tests a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) given before surgery to 22 patients with resectable esophageal squamous cell carcinoma. The main goal is to see if the cancer disappears completely after treatment. If it works, th…

This early-stage study tests a new cell therapy called CHT101 in 30 adults whose malignant brain tumors have come back or worsened despite standard treatment. The therapy uses specially engineered cells to target a protein called CD70 found on tumor cells. The main goal is to che…

This study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled…

This study tests a new combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare and fast-growing type of cancer called large-cell neuroendocrine carcinoma, which can start in the lung or elsewhere in the body. The goal …

This study tests a new approach for early triple-negative breast cancer. Patients receive an immunotherapy drug (QL1706) plus chemotherapy. After four cycles, scans and biopsies check if the tumor has disappeared. If it has, patients skip the heart-toxic chemo (anthracyclines) an…

This study tests a new combination of drugs (tunlametinib, chemotherapy, and cetuximab β) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and is safe. About 28 adults who have not ha…

This study tests a combination of two drugs, entinostat and oral paclitaxel, in people with a certain type of advanced breast cancer (HR+HER2-). The goal is to see if this treatment can slow down the cancer's growth. About 50 adults who have already tried 2 to 4 other treatments …

This study tests a combination of two drugs, Sacituzumab Tirumotecan and Toripalimab, as a first treatment for people with a type of advanced breast cancer called PD-L1 positive triple-negative breast cancer. The goal is to see if the combo shrinks tumors and controls the disease…

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…

This study tests a new treatment for mantle cell lymphoma, a rare blood cancer. It combines chemotherapy with targeted drugs to see if it can keep the cancer from coming back. The study involves 45 people who have not been treated before, and uses scans and blood tests to guide t…

This study tests whether adding the immunotherapy drug camrelizumab to chemotherapy and radiation before surgery can eliminate all signs of early-stage triple-negative breast cancer. About 43 women with newly diagnosed, untreated disease will receive the combination for 12 weeks,…

This study tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. The treatment includes chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy. The goal is to see if this approach can shrin…

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. The approach combines the drug bemotuzumab with standard chemotherapy and another drug called anlotinib, followed by chest radiation. The goal is to see if t…

This study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can lower the chance of liver cancer coming back in people with early-stage (stage IA) liver cancer who are expected to have a narrow surgical margin. About 60 participants will be randomly ass…

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…

This study will follow 500 adults with HER2-positive advanced breast cancer who are starting treatment with pyrotinib. Researchers want to see how well the drug works and how safe it is in everyday medical practice, not just in a controlled trial. The main goal is to measure how …

This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This study tests a combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) as a second treatment for people with advanced liver cancer that did not respond to or stopped responding to initial immunotherapy. The goal is to see if this new approach can shrink tumo…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …

This study tests a combination of two drugs (sacituzumab tirumotecan and toripalimab) given before surgery to people with stage II-IIIB non-small cell lung cancer that lacks certain genetic mutations. The goal is to see if this treatment can shrink or eliminate the cancer before …

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This study tests whether adding surufatinib to standard chemotherapy before surgery helps more people with high-risk or borderline resectable pancreatic cancer have a complete tumor removal. About 106 adults aged 18-75 with no prior treatment will be randomly assigned to receive …

This study tests whether giving two drugs (anlotinib and benmelstobart) before surgery can help preserve kidney function and improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drugs before a partial nephrectomy or have surgery…

This study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…

This phase 2 trial tests whether adding an allergy medicine (diphenhydramine) to standard immunotherapy (toripalimab) and chemotherapy helps shrink lung tumors before surgery and prevents cancer from coming back after surgery. About 120 adults with stage IIA-IIIB non-small cell l…

This study tests a drug called romiplostim N01 in 68 breast cancer patients whose platelet counts dropped too low after chemotherapy. The goal is to see if a weekly injection can safely bring platelet levels back up within two weeks, helping patients continue their cancer treatme…

This study tests whether a combination of two anti-nausea drugs (NEPA plus megestrol acetate) works better than the standard regimen (NEPA plus dexamethasone) for preventing nausea and vomiting in breast cancer patients receiving T-DXd therapy. 120 participants will be randomly a…

This study tests a new painkiller called anrikefon in 114 people recovering from laparoscopic stomach cancer surgery. The drug aims to control pain with fewer side effects like nausea and drowsiness than standard opioids. Researchers will measure how much extra opioid pain medici…

This study looks at 300 lung cancer patients who had immunotherapy before surgery but still had cancer cells left after the operation. Researchers will use advanced gene testing on leftover tumor samples to find hidden genetic changes. The goal is to see if these gene changes aff…

This study looks at 860 Chinese patients with advanced kidney cancer to see which order of treatments works better: starting with one drug combo and switching to another, or the reverse. The goal is to find the best sequence to help patients live longer and feel better. Participa…